Drug research

Aglatimagene besadenovec

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as AdV-tk; CAN-2409

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaNCT02446093	CADL	Phase 2	Unknown	2025-12Estimated
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCNCT04495153	CADL	Phase 2	Active not recruiting	2024-12-31Actual

CADLUnknownPrimary completion: 2025-12 · Estimated

Trial details

CADLActive not recruitingPrimary completion: 2024-12-31 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.